bluebird bio, Inc. (LON:0HOH)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 31.38M |
| Revenue (ttm) | 39.63M |
| Net Income (ttm) | -218.48M |
| Shares Out | n/a |
| EPS (ttm) | -25.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 61 |
| Average Volume | 1,152 |
| Open | 7.95 |
| Previous Close | 7.94 |
| Day's Range | 7.94 - 8.06 |
| 52-Week Range | 0.89 - 8.06 |
| Beta | n/a |
| RSI | 48.70 |
| Earnings Date | Mar 4, 2025 |
About bluebird bio
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company’s product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to... [Read more]
Financial Performance
In 2023, bluebird bio's revenue was $29.50 million, an increase of 720.04% compared to the previous year's $3.60 million. Losses were -$211.91 million, -8.00% less than in 2022.
Financial numbers in USD Financial StatementsNews
bluebird bio Stock Alert - Kehoe Law Firm, P.C. Investigating the Fairness and Adequacy of the Proposed Acquisition of bluebird bio by Investment Firms in Collaboration with Biotech Execs
PHILADELPHIA, PA / ACCESS Newswire / February 21, 2025 / Kehoe Law Firm, P.C. is investigating potential claims on behalf of investors of bluebird bio (NASDAQ:BLUE) regarding the adequacy and fairness...
Shareholder Alert: Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating bluebird (Nasdaq: BLUE) for possible breaches of fiduciary duty and other violations of law in its transaction with Carlyle and SK Capital. Click...
What's Going On With Gene Therapy Company Bluebird Bio Stock Today?
bluebird bio agrees to be acquired by ... Full story available on Benzinga.com
BLUE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of bluebird bio, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of bluebird bio, Inc. (NASDAQ: BLUE) to Carlyle Group and SK Capital Partners, LP is fair to...
Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch
Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners, ending its tumultuous journey in the public markets as it struggled with a severe cash crun...
bluebird bio announces take-private deal with Carlyle and SK Capital
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today announced that it has entered into a definitive agreement to be acquired by funds managed by global investment ...
High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models
Deshawn "DJ" Chow is one of just over 100 sickle cell patients who have undergone treatment with new gene therapies. CVS Health CEO David Joyner said private insurers and employer-sponsored health pla...
HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws'
In a court filing on Monday, the Department of Health and Human Services (HHS) challenged Vertex Pharmaceuticals Inc (NASDAQ: VRTX), defending its stance that the company’s proposed fertility service...
Bluebird Bio (BLUE) Shares Surge Amid Market Activity
Bluebird Bio (BLUE) Shares Surge Amid Market Activity
2seventy bio: All In On Abecma Multiple Myeloma Treatment
Explore the investment prospects of 2seventy Bio, a spin-off from bluebird bio, in the competitive field of cell therapies compared to its peers. Click to read.
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
Jefferies has upgraded Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), citing the company’s robust cystic fibrosis base business and the additional upside from the new LNP/ mRNA therapy (around $1 billio...
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced new and updated data from LYFGENIA™ (lovotobegligene autotemcel, or lovo-cel) gene therapy for patients with sickl...
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with betibeglogene...
bluebird bio announces 1-for-20 reverse stock split; shares tumble
bluebird bio Announces 1-for-20 Reverse Stock Split
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it will proceed with a 1-for-20 reverse stock split (“Reverse Stock Split”)...
CMS rolls out new payment model for Vertex, bluebird gene therapies
Bluebird bio (BLUE) and Vertex (VRTX) have entered into outcome-based agreements with CMS aimed at expanding patient access to their gene therapies for sickle cell disease.
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio”) today announced it has reached an agreement with the Center for Medicare and Medicaid Innovation to offer an outc...
FDA investigates risk of blood cancers from bluebird bio's gene therapy
The U.S. Food and Drug Administration said on Wednesday it is investigating reports of blood cancers in patients who were treated with bluebird bio's gene therapy Skysona.
My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys
Investment activity in October focused on Business Development Companies, with $1,300 added to the market. Adjusted dividend income in October of $789, up 25% Y/Y and up 11% sequentially. Main picks i...
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
On Thursday, Bluebird Bio Inc. BLUE reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a year ago, beating the consensus loss of 36 cents.
bluebird bio, Inc. (BLUE) Q3 2024 Earnings Call Transcript
bluebird bio, Inc. (NASDAQ:BLUE) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Courtney O'Leary - Director, Investor Relations Andrew Obenshain - Chief Executive ...
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported third quarter results and business highlights for the quarter ended September 30,...
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it partially adjourned its annual meeting of stockholders (“Annual Meeting”...
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio presenting data from gene therapy programs in Sickle Cell Disease and Beta-Thalassemia at the 66th ASH Annual Meeting and Exposition.